Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding.
Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
Vertex announced on Tuesday that eligible patients in Ireland, Denmark, and Germany will have access to Alyftrek shortly after receiving regulatory approval from the relevant authorities.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing.
However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.
